Suchergebnisse - "Best, Jennie H"

PubPharm (17)

11

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

enthalten in: Journal of medical economics | 2012

von Guillermin, A. | Lloyd, A. | Best, J. | +3

12

Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US

enthalten in: Journal of medical economics | 2012

von Samyshkin, Y. | Guillermin, A. | Best, J. | +2

13

Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment

enthalten in: Diabetes care | 2011

von Best, J. | Rubin, R. | Peyrot, M. | +4

14

Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs

enthalten in: Current medical research and opinion | 2010

von Peyrot, M. | Rubin, R. | Polonsky, W. | +1

15

The economic value of reducing medication dosing frequency with drug delivery technologies : an evidence assessment

enthalten in: Journal of medical economics | 2010

von Cheng, M. | Alfonso, R. | Best, J. | +3

16

Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2005

von Best, J. | Hornberger, J. | Proctor, S. | +2

17

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma

enthalten in: Cancer | 2005

von Hornberger, J. | Best, J.